Solid pharmaceutical preparation dissolved in oral cavity

A solid preparation and intraoral technology, applied in the field of solid preparations for intraoral dissolution, can solve problems such as inability to maintain the effect

Inactive Publication Date: 2007-10-03
KOWA CO LTD
View PDF2 Cites 6 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Therefore, the current situation is that, even if a drug that has a direct bactericidal

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Solid pharmaceutical preparation dissolved in oral cavity

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0044] Mix 1 g of cetylpyridinium chloride (manufactured by Wako Pure Chemical Industries, Ltd., trade name cetylpyridinium chloride), 183.8 g of sorbitol, and 3 g of sodium saccharin, and use a mixture obtained by dissolving 8 g of hydroxypropyl cellulose in 40 g of ethanol. Wet granulation, the granulated material was dried and then sized to obtain 195.8 g of inner core sized powder. 2 g of magnesium stearate, 2 g of menthol powder, and 0.2 g of citrus flavor were mixed with the obtained sized powder, and uncoated inner core tablets with a diameter of 8 mm and a mass of 200 mg were produced with a rotary tablet machine. Mix tranexamic acid (manufactured by Daiichi Pharmaceutical Co., Ltd., trade name tranexamic acid) 250g, aspartame 30g, dipotassium glycyrrhizinate 13g, mannitol 442.2g, crospovidone 40g, magnesium stearate 8g, peppermint 16 g of alcohol powder and 0.8 g of grapefruit flavor were used to compress and coat the mixed powder with 800 mg per piece of the obtained...

Embodiment 2

[0046] Mix 1 g of cetylpyridinium chloride (manufactured by Wako Pure Chemical Industries: trade name cetylpyridinium chloride), 292.7 g of mannitol, 3 g of magnesium stearate, 3 g of menthol powder, and 0.3 g of citrus flavor, and use direct powder compression method, The mixed powder was made into an uncoated core tablet with a diameter of 9 mm and a mass of 300 mg with a rotary tablet press. Mix tranexamic acid (manufactured by Daiichi Pharmaceutical Co., Ltd.: trade name tranexamic acid) 400g, aspartame 30g, dipotassium glycyrrhizinate 13g, sorbitol 292.2g, crospovidone 40g, stearyl fumaric acid 8 g of sodium, 16 g of menthol powder, and 0.8 g of grapefruit flavor were used to compress and coat the mixed powder with 800 mg per tablet of the uncoated core tablets obtained using a coating tablet press to obtain a solid preparation with a diameter of 13.5 mm and a mass of 1100 mg.

Embodiment 3

[0048] Mix 2 g of cetylpyridinium chloride (manufactured by Wako Pure Chemical Industries: trade name cetylpyridinium chloride), 184.3 g of xylitol, 184.3 g of erythritol, and 5 g of sodium saccharin, and dissolve 16 g of hydroxypropyl cellulose in 80 g of ethanol The mixed solution obtained in the above method was subjected to wet granulation, and the granulated material was dried and then sized to obtain 391.6 g of inner core sized powder. 4 g of magnesium stearate, 4 g of menthol powder, and 0.4 g of citrus flavor were mixed with the obtained sized powder, and an uncoated inner core tablet with a diameter of 10 mm and a mass of 400 mg was produced with a rotary tablet machine. Mix tranexamic acid (manufactured by Daiichi Pharmaceutical Co., Ltd., trade name tranexamic acid) 250g, aspartame 30g, dipotassium glycyrrhizinate 13g, sorbitol 576g, microcrystalline cellulose 100g, magnesium stearate 5g, menthol 25 g of powder and 1 g of grapefruit flavor were used to compress and ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

A solid pharmaceutical preparation dissolved in oral cavity, comprising part containing an intraoral antiinflammatory ingredient of 45 sec to 2 min disintegration time, exhibited in a disintegration test according to the Japanese Pharmacopoeia disintegration test, and part containing an intraoral antimicrobial ingredient of > 3 min disintegration time. This solid pharmaceutical preparation enables to easily realize simultaneous accomplishment of treatment of throat pain and intraoral sustained sterilization by means of a single pharmaceutical preparation.

Description

technical field [0001] The present invention relates to a solid preparation for dissolving in the oral cavity, which can easily treat pains such as the throat and continuously sterilize the oral cavity simultaneously with a single preparation. Background technique [0002] With the OA of air-conditioning, public hazards such as air pollution, and environmental pollution of climate, water and soil, the number of patients complaining of sore throat is increasing. In general, a sore throat is treated by directly sterilizing the affected part from the outside, and by allowing the drug to enter the blood circulation to internally suppress the inflammation that causes the sore throat. For example, as a method of directly sterilizing an affected part from the outside, the mouth is gargled with a gargle containing a fungicide such as povidone iodine or cetylpyridinium chloride. Alternatively, a method such as dissolving a buccal tablet containing a bactericide in the mouth to steri...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K9/24A61P31/04A61K31/195A61P29/00A61K31/4425
CPCA61K9/0056A61K31/195A61K31/4425A61P29/00A61P31/04A61K9/209
Inventor 前谷茂宏狩野祐一郎冈崎洋行川岛弘行
Owner KOWA CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap